Skip to Content

Science to Secure

Our Future

Aerium is dedicated to the discovery & development of antibodies and small molecule antivirals against SARS-CoV-2 and other epidemic & pandemic threats.

Our Science

Aerium Therapeutics is developing medicines to protect the world against pandemic and epidemic threats.

Aerium’s current focus is on the protection of immunocompromised persons, who account for approximately 3-6% of the adult population in the US. These individuals’ immune systems may not respond fully to vaccination, leaving them vulnerable to COVID-19 and severe outcomes of the disease. Our lead program is a combination of two long-acting monoclonal antibodies against SARS-CoV-2 that have potent activity against all major variants identified to date and present a high barrier to future virus evasion.

Aerium is also collaborating with the University of California, San Francisco to evaluate an anti-SARS-CoV-2 antibody for the treatment of Long COVID, which is estimated to affect up to 18 million persons in the US alone.

Aerium’s fully integrated discovery platform is derived from a broad network of international experts and research infrastructure at leading medical institutions. Capabilities include a BSL-3/P3 laboratory for advanced viral assays, Cryo-EM expertise for rapid viral protein characterization, and an active antibody discovery platform, which support our lead program and enable further expansion of our pipeline.

Our team


Board of Directors



Contact us

Message Us

    Back to top